Transformation of a Chronic Myeloproliferative Neoplasm to Acute Myelogenous Leukemia: Does Anything Work?
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Transformation of a Chronic Myeloproliferative Neoplasm to Acute Myelogenous Leukemia: Does Anything Work?
Authors
Keywords
-
Journal
Current Hematologic Malignancy Reports
Volume 7, Issue 1, Pages 78-86
Publisher
Springer Nature
Online
2011-12-14
DOI
10.1007/s11899-011-0107-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia
- (2011) H. Makishima et al. BLOOD
- Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors
- (2011) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes
- (2011) Rafael Bejar et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
- (2011) Animesh Pardanani et al. JOURNAL OF CLINICAL ONCOLOGY
- Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies
- (2011) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms
- (2010) F. X. Schaub et al. BLOOD
- Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)
- (2010) S. Thepot et al. BLOOD
- Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
- (2010) Stefan Gross et al. JOURNAL OF EXPERIMENTAL MEDICINE
- IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
- (2010) A Tefferi et al. LEUKEMIA
- LNK mutation studies in blast-phase myeloproliferative neoplasms and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations
- (2010) A Pardanani et al. LEUKEMIA
- Deletions of the transcription factor Ikaros in myeloproliferative neoplasms
- (2010) R Jäger et al. LEUKEMIA
- High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression
- (2010) J Boultwood et al. LEUKEMIA
- Somatic Mutations ofIDH1andIDH2in the Leukemic Transformation of Myeloproliferative Neoplasms
- (2010) Anthony Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms
- (2010) Aravind Ramakrishnan et al. Expert Review of Hematology
- AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms
- (2009) Y. Ding et al. BLOOD
- Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm
- (2009) P. A. Beer et al. BLOOD
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
- (2009) J. W. Vardiman et al. BLOOD
- The Interferon Consensus Sequence Binding Protein (ICSBP/IRF8) Activates Transcription of theFANCFGene during Myeloid Differentiation
- (2009) Gurveen Saberwal et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
- (2009) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
- (2009) Alfonso Quintás-Cardama et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutations of ASXL1 gene in myeloproliferative neoplasms
- (2009) N Carbuccia et al. LEUKEMIA
- TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
- (2009) A Tefferi et al. LEUKEMIA
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
- (2009) Lenny Dang et al. NATURE
- Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
- (2009) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
- (2009) M. Tahiliani et al. SCIENCE
- Nuclear translocation of urokinase-type plasminogen activator
- (2008) V. Stepanova et al. BLOOD
- The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms
- (2008) C. S. Tam et al. BLOOD
- Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
- (2008) J.-J. Kiladjian et al. BLOOD
- Risk factors for leukemic transformation in patients with primary myelofibrosis
- (2008) Jocelin Huang et al. CANCER
- Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin
- (2008) Anthony W. Tolcher et al. JOURNAL OF CLINICAL ONCOLOGY
- A Sensitive Detection Method for MPLW515L or MPLW515K Mutation in Chronic Myeloproliferative Disorders with Locked Nucleic Acid-Modified Probes and Real-Time Polymerase Chain Reaction
- (2008) Alessandro Pancrazzi et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
- (2008) A Tefferi et al. LEUKEMIA
- Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice
- (2007) R. Tiedt et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started